These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37980651)

  • 1. STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.
    Song Z; Zhao Z; Zhu S; Jin Q; Shi Y; Zhang S; Wang Z; Wang Y; Zhao Z
    Cancer Biomark; 2023; 38(4):505-522. PubMed ID: 37980651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of six-transmembrane epithelial antigen of prostate 3 promotes the migration and invasion and predicts unfavorable prognosis in glioma.
    Deng L; Zeng S; Yi Q; Song L
    PeerJ; 2023; 11():e15136. PubMed ID: 37009153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IQGAP3 promotes the progression of glioma as an immune and prognostic marker.
    Gao X; Ge J; Gao X; Mei NA; Su Y; Shan S; Qian W; Guan J; Zhang Z; Wang L
    Oncol Res; 2024; 32(4):659-678. PubMed ID: 38560572
    [No Abstract]   [Full Text] [Related]  

  • 4. PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K/AKT/mTOR pathway.
    Wang Y; Zhang S; Zhao Z; Jin Q; Wang Z; Song Z; Liu L; Zhao Z
    Immunobiology; 2024 May; 229(3):152802. PubMed ID: 38569452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylsulfatase D is a prognostic biomarker that promotes glioma cells progression through JAK2/STAT3 pathway and M2 macrophage infiltration.
    Song Z; Zhao Z; Zhu S; Jin Q; Zhang S; Wang Z; Shen B; Wang Z; Zhao Z
    Front Oncol; 2023; 13():1228426. PubMed ID: 37766864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinster homolog 2 reduces malignancies of glioblastoma via PTEN/PI3K/AKT pathway.
    Liang W; Liu M; Su Y; Wen Y; Wang L; Shan J; Zhao J; Xie K; Wang J
    IUBMB Life; 2024 Mar; 76(3):140-160. PubMed ID: 37728571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial-mesenchymal.
    Wei H; Li Z; Zhao Y; Zhu S; Wen S; Quan C
    Cancer Rep (Hoboken); 2023 Aug; 6(8):e1824. PubMed ID: 37344930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STEAP3 can predict the prognosis and shape the tumor microenvironment of clear cell renal cell carcinoma.
    Wu J; Bi Q; Zheng X; Cao H; Hao C; Sun Z; Wang W
    BMC Cancer; 2022 Nov; 22(1):1204. PubMed ID: 36424540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
    Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
    Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GDF15 expression in glioma is associated with malignant progression, immune microenvironment, and serves as a prognostic factor.
    Guo L; Chen Y; Hu S; Gao L; Tang N; Liu R; Qin Y; Ren C; Du S
    CNS Neurosci Ther; 2022 Jan; 28(1):158-171. PubMed ID: 34697897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SP140 inhibitor suppressing TRIM22 expression regulates glioma progress through PI3K/AKT signaling pathway.
    Li X; Li G; Li L; Gao B; Niu X; Wang Y; Wang Z
    Brain Behav; 2024 Mar; 14(3):e3465. PubMed ID: 38468469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes.
    Ma C; Bao Y; Xu J; Xiao B; Li H
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):47-62. PubMed ID: 36528831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
    Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
    J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.